Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Growth Hormone
Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation.
Peptide B
Growth Hormone
Selective growth hormone secretagogue with minimal side effects.
Typical vial
2 mg
Typical dose
100-300 mcg
Half-life
~30 minutes (no DAC) / 6-8 days (with DAC)
FDA status
Not FDA approved for human use.
Typical vial
5 mg
Typical dose
100-300 mcg
Half-life
~2 hours
FDA status
Not FDA approved for human use. Clinical development discont…
CJC-1295 effects
Ipamorelin effects
CJC-1295 side effects
Ipamorelin side effects
CJC-1295 dosing ranges
Anti-aging and recovery (Mod GRF)
100 mcg · Once to three times daily (SubQ) · 8-12 weeks
Body composition (Mod GRF + Ipamorelin)
100-300 mcg · Two to three times daily · 8-12 weeks
CJC-1295 with DAC
1000-2000 mcg · Once or twice weekly · 8-12 weeks
Ipamorelin dosing ranges
GH optimization and anti-aging
100-300 mcg · Two to three times daily (SubQ) · 8-12 weeks
Combined with CJC-1295 (Mod GRF)
100-200 mcg · Two to three times daily · 8-12 weeks
CJC-1295: Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation. Typical dose 100-300 mcg. Ipamorelin: Selective growth hormone secretagogue with minimal side effects. Typical dose 100-300 mcg. Both fall under the Growth Hormone category.
Stacking CJC-1295 with Ipamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
CJC-1295 is typically dosed: Once to three times daily (SubQ) for Anti-aging and recovery (Mod GRF); Two to three times daily for Body composition (Mod GRF + Ipamorelin); Once or twice weekly for CJC-1295 with DAC. Ipamorelin is typically dosed: Two to three times daily (SubQ) for GH optimization and anti-aging; Two to three times daily for Combined with CJC-1295 (Mod GRF).
CJC-1295: Not FDA approved for human use. Ipamorelin: Not FDA approved for human use. Clinical development discontinued by Novo Nordisk.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free